Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-05-02
2008-10-07
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S353000, C544S354000, C544S355000, C544S356000
Reexamination Certificate
active
07432270
ABSTRACT:
This invention relates to N-aroyl cyclic amine derivatives and their use as orexin antagonistswherein:Y represents a bond, oxygen, or a group (CH2)n, wherein n represents 1, 2 or 3;m represents 1, 2, or 3; p represents ) or 1; X is NR, wherein R is H or (C1-4)alkyl; Ar1is aryl, or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; any of which may be optionally substituted; A2represents phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by R1and further optional substituents; or Ar2represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O and S; R1represents hydrogen, optionally substituted (C1-4)alkoxy, halo, cyano, optionally substituted (C1-6)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclyl group containing up to 4 heteroatoms selected from N, O and S; when Ar1is aryl p is not 1, or a pharmaceutical acceptable salt thereof.
REFERENCES:
patent: 5547978 (1996-08-01), Christensen et al.
patent: 6326379 (2001-12-01), Macor et al.
patent: 6677354 (2004-01-01), Branch et al.
patent: 6706720 (2004-03-01), Atwal et al.
patent: 2004/0180887 (2004-09-01), Branch et al.
patent: 2004/0192673 (2004-09-01), Gaillard et al.
patent: 2004/0215014 (2004-10-01), Chan et al.
patent: 2006/0040937 (2006-02-01), Branch et al.
patent: WO 00/08015 (2000-02-01), None
patent: WO 00/12077 (2000-03-01), None
patent: WO 00/71508 (2000-11-01), None
patent: WO 01/40231 (2001-06-01), None
patent: WO 01/96302 (2001-12-01), None
patent: WO 02/44172 (2002-06-01), None
Lang et al., J. Med. Chem., 2004, 47, p. 1153.
Smart et al., Euro. J. Pharm., 2002, 440, p. 199.
Smart et al., “Orexins and the treatment of obesity”, European Journal of Pharmacology 440 (2002) 199-212.
Lang et al., “Structure-Activity Studies, etc.,” J. Med. Chem. 2004, 47, 1153-1160.
Kilduff et al., “The hypocretin/orexin, etc.,” Trends Neurosi. 2000, 23, 359-365.
Taheri et al., “The Role of Hypocretins, etc.,” Annu. Rev. Neurosci., 2002, 25: 283-313.
Cai et al., “Antagonists of the orexin receptors”, Expert Opin. Ther. Patents (2006) 16(5), 631-646.
King, “Bioisoteres, Conformational, etc.,” Med. Chem: Principle and Practice (1994), 206-208.
Patini et al., “Bioisosterism: A Rational, etc.,” Chem. Rev. 1996, 96, 3147, 3148 and 3170.
Rubini et al., “Synthesis of, etc.,” Tetrahedron, 42 (21), 6039-6045, 1986.
Mori, et al., “New Synthesis of Pyrrolo-1,4-benzodiazepines by Utilizing Palladium-Catalyzed Carbonylation”.Chem. Pharm. Bull., 32(10): 3840-3847 (1984).
Defoin, et al., “Asymmetric Diels-Alder-Cycloadditions with Chiral Carbamoyl Dienophiles”.Helv. Chim. Acta, 75(1): 109-123 (1992).
Langmead et al. Br. J. Pharmacol., 141: 340-346 (2004).
Porter et al. Bioorg. & Med. Chem. Lett., 11: 1907-1910 (2001).
Duxon et al. Psychopharmacology, 153: 203-209 (2001).
White et al. Peptides, 26: 2331-2338 (2005).
Ishii et al. Behav. Brain Res., 160: 11-24 (2005).
Ishii et al. Behav. Brain Res., 157: 331-341 (2005).
Ishii et al. Physiol. & Behav., 81: 129-140 (2004).
Smith et al. Neurosci. Lett., 341: 256-258 (2003).
Haynes et al. Regulatory Peptides, 104: 153-159 (2002).
Bingham et al. Pain, 92: 81-90 (2001).
Rodgers et al. Eur. J. Neurosci., 13: 1444-1452 (2001).
Smart et al. Br. J. Pharmacol. 132: 1179-1182 (2001).
Jones et al. Psychopharmacology, 153: 210-218 (2001).
Haynes et al. Regulatory Peptides, 96: 45-51 (2000).
Rodgers et al. Neuropeptides, 36(5): 303-325 (2002).
Mori et al. Chem. Pharm. Bull., 32(10): 3840-3847 (1984).
Defoin et al. Helv. Chim. Acta, 75(1): 109-123 (1992).
Boutrel et al.PNAS, 102(52): 19168-19173 (2005).
Borgland et al.Neuron, 49: 589-601 (2006).
Harris et al.Nature, 437: 556-559 (2005).
Brisbare-Roch et al.Nature Medicine, 13(2): 150-155 (2007).
Hagan et al.Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).
Piper et al.Eur. J. Neurosci., 12: 726-730 (2000).
Patani et al.Chem. Rev., 96: 3147-3176 (1996).
Branch Clive Leslie
Coulton Steven
Johns Amanda
Johnson Christopher Norbert
Porter Roderick Alan
Kinzig Charles M.
McCarthy Mary E.
Morris Patricia L.
Sieburth Kathryn L.
SmithKline Beecham p.l.c.
LandOfFree
N-aroyl cyclic amines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-aroyl cyclic amines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-aroyl cyclic amines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3992762